AA
SRNE

AlphaMark Advisors’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

AlphaMark Advisors’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-2,135
Closed – – 849
2024
Q2 		$0 Hold
2,135
– – ﹤0.01% 857
2024
Q1 		$0 Hold
2,135
– – ﹤0.01% 839
2023
Q4 		$0 Sell
2,135
-1,000
-32% – ﹤0.01% 821
2023
Q3 		$0 Hold
3,135
– – ﹤0.01% 787
2023
Q2 		$1K Hold
3,135
– – ﹤0.01% 608
2023
Q1 		$1K Hold
3,135
– – ﹤0.01% 602
2022
Q4 		$3K Sell
3,135
-865
-22% -$1.15K ﹤0.01% 504
2022
Q3 		$6K Hold
4,000
– – ﹤0.01% 491
2022
Q2 		$8K Hold
4,000
– – ﹤0.01% 428
2022
Q1 		$9K Buy
4,000
+2,500
+167% +$7.8K ﹤0.01% 421
2021
Q4 		$7K Buy
+1,500
New +$9.31K ﹤0.01% 435

Other funds holding SRNE

LCM
Lattice Capital Management Kirkland, Washington $56.9M AUM 49.15% 1-Year Est. Return
HAG
HighPoint Advisor Group Downers Grove, Illinois $2.39B AUM 28.86% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

AlphaMark Advisors's SRNE Position: Q3 2024 in Review

AlphaMark Advisors sold out of Sorrento Therapeutics, Inc. (SRNE) in Q3 2024, closing a stake of 2,135 shares.

AlphaMark Advisors first reported a position in SRNE in Q4 2021 and held it in 11 quarters. The position peaked at $9K in Q1 2022. 4 funds tracked by Wall St. Rank hold SRNE as of Q3 2024.

  • AlphaMark Advisors reported no remaining Sorrento Therapeutics, Inc. position as of Q3 2024 after selling out during the quarter.
  • AlphaMark Advisors sold 2,135 Sorrento Therapeutics, Inc. shares in Q3 2024.
  • AlphaMark Advisors first reported a position in Sorrento Therapeutics, Inc. in Q4 2021 and held it in 11 quarters.
  • AlphaMark Advisors's Sorrento Therapeutics, Inc. position peaked at $9K in Q1 2022.
  • 4 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q3 2024.

Based on AlphaMark Advisors's 13F filing for Q3 2024, filed 16 Oct 2024.